Bone Biologics Corp. (NASDAQ:BBLG) Stock Short Interest Drops 54.0%

Bone Biologics Corp. (NASDAQ:BBLG) was the target of a significant decrease in short interest in October. As of October 15th, there was short interest totaling 22,777 shares, a decrease of 54.0% from the September 30th total of 49,512 shares. Based on an average daily trading volume, of 41,660 shares, the days-to-cover ratio is presently 0.5 days. Currently, 0.9% of the company’s stock are sold short.

Bone Biologics Stock Down 2.0%

BBLG stock traded down $0.01 during trading on Friday, reaching $0.38. The stock had a trading volume of 14,407 shares, compared to its average volume of 39,781. Bone Biologics has a one year low of $0.36 and a one year high of $2.39. The company’s 50 day moving average is $0.49 and its two-hundred day moving average is $1.06. The company has a market capitalization of $1.29 million, a price-to-earnings ratio of -0.33 and a beta of 0.90.

Bone Biologics (NASDAQ:BBLG) last posted its quarterly earnings data on Monday, October 26th. The company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.02. As a group, research analysts predict that Bone Biologics will post -1.23 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Bone Biologics in a research note on Thursday, October 22nd. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the company currently has an average rating of “Sell”.

About Bone Biologics

Bone Biologics Corporation is a biotechnology and medical device company focused on developing regenerative products for bone repair and spinal fusion. Its technology platform is based on NELL-1, a recombinant human protein designed to stimulate bone growth and support the formation of new bone.

The company’s lead development programs combine NELL-1 with resorbable bone-graft scaffolds for use in orthopedic and spinal procedures. These products are intended to provide surgeons with alternatives or supplements to conventional bone-grafting approaches, with an initial emphasis on spinal fusion applications.

Bone Biologics has conducted its research and development activities in collaboration with academic and medical institutions, including researchers associated with the University of California, Los Angeles.